On October 20, 2025, AstraZeneca announced the US FDA approval of Tezspire (tezepelumab) for treating chronic rhinosinusitis with nasal polyps, marking a significant expansion of its use beyond severe asthma. This approval aims to improve the quality of life for approximately 320 million people globally affected by the condition by significantly reducing the need for surgery and systemic corticosteroids.